Asset Details
Do you wish to reserve the book?
Peptide chirality and opioid receptor modulation: Hepatoprotective effect of d-Met-enkephalin in acetaminophen-induced liver injury
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Peptide chirality and opioid receptor modulation: Hepatoprotective effect of d-Met-enkephalin in acetaminophen-induced liver injury
Do you wish to request the book?
Peptide chirality and opioid receptor modulation: Hepatoprotective effect of d-Met-enkephalin in acetaminophen-induced liver injury
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Peptide chirality and opioid receptor modulation: Hepatoprotective effect of d-Met-enkephalin in acetaminophen-induced liver injury
2025
Overview
-Met-enkephalin is a neuropeptide known to exert protective effects in various experimental models of autoimmune and inflammatory diseases. These effects are mediated through opioid receptors and can be abolished by the opioid receptor antagonist naltrexone. Investigation of peptide enantiomerism and the incorporation of d-amino acids are crucial for designing novel peptides with altered structural and biological properties compared with their native l-forms. Since no data are currently available on the properties or biological activity of the d-Met-enkephalin enantiomer, we evaluated its hepatoprotective potential in a mouse model of acetaminophen-induced hepatotoxicity. Male CBA mice were treated with d-Met-enkephalin, and hepatoprotection was assessed by measuring plasma alanine aminotransferase (ALT) and aspartate amino-transferase (AST) activities, along with histological liver necrosis scores. The peptide’s secondary structure and antisense peptide binding were analysed using circular dichroism and fluorescence spectroscopy, respectively.
-Met-enkephalin demonstrated dose-dependent hepatoprotective effects within the range of 0.5–20 mg kg–1, with maximal protection observed at 5 mg kg
, a dose comparable to that of the l-enantiomer (7.5 mg kg
). This preservation of biological activity may be attributed to the presence of the achiral amino acid glycine at positions 2 and 3, which maintains the functional conformation of the d-enantiomer. The role of opioid receptor involvement was further examined through direct receptor blockade using naltrexone and indirect inhibition with the antisense peptide IPPKY.
Publisher
Sciendo,De Gruyter Brill Sp. z o.o., Paradigm Publishing Services,Hrvatsko farmaceutsko društvo
Subject
/ Alanine Transaminase - blood
/ Animals
/ Aspartate Aminotransferases - blood
/ Chemical and Drug Induced Liver Injury - drug therapy
/ Chemical and Drug Induced Liver Injury - metabolism
/ Chemical and Drug Induced Liver Injury - pathology
/ Chemical and Drug Induced Liver Injury - prevention & control
/ Dose-Response Relationship, Drug
/ Enkephalin, Methionine - administration & dosage
/ Enkephalin, Methionine - chemistry
/ Enkephalin, Methionine - pharmacology
/ Liver
/ Male
/ Mice
/ Narcotic Antagonists - pharmacology
/ Peptides
/ Protective Agents - pharmacology
/ Receptors, Opioid - drug effects
